| [1] |
GENITSARIDI I S P, SALIM A S S F, TOMIC D J S, et al. Idf Diabetes Atlas: Global, Regional and National Diabetes Prevalence Estimates for 2024 and Projections for 2050[J]. SSRN, 2025:1-2.doi: 10.1016/j.diabres.2021.109119 .
doi: 10.1016/j.diabres.2021.109119
|
| [2] |
International Diabetes Federation. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes 2025[J]. Diabetes Res Clin Pract, 2025, 224: 112238. doi: 10.1016/j.diabres.2025.112238 .
doi: 10.1016/j.diabres.2025.112238
|
| [3] |
袁慧娟, 杨俊朋, 邓欣如, 等. 成人早发2型糖尿病诊治专家共识[J]. 中华实用诊断与治疗杂志, 2022, 36(12): 1189-1198. doi:10.13507/j.issn.1674-3474.2022.12.001 .
doi: 10.13507/j.issn.1674-3474.2022.12.001
|
| [4] |
ZHAO M, SONG L, SUN L, et al. Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study[J]. Diabetes Care, 2021, 44(6): 1426-1432.doi: 10.2337/dc20-2375 .
doi: 10.2337/dc20-2375
|
| [5] |
MISRA S, KE C, SRINIVASAN S, et al. Current insights and emerging trends in early-onset type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2023, 11(10): 768-782. doi: 10.1016/S2213-8587(23)00225-5 .
doi: 10.1016/S2213-8587(23)00225-5
|
| [6] |
WU Y, WANG Y, ZHANG J, et al. Early-onset of type 2 diabetes mellitus is a risk factor for diabetic nephropathy progression: A biopsy-based study[J]. Aging (Albany NY), 2021, 13(6): 8146-8154. doi: 10.18632/aging.202624 .
doi: 10.18632/aging.202624
|
| [7] |
LIU J J, LIU S, GURUNG R L, et al. Risk of progressive chronic kidney disease in individuals with early-onset type 2 diabetes: A prospective cohort study[J]. Nephrol Dial Transplant, 2020, 35(1): 115-121.doi: 10.1093/ndt/gfy211 .
doi: 10.1093/ndt/gfy211
|
| [8] |
KE C, SHAH B R, LUK A O, et al. Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults[J]. Diabetes Obes Metab, 2020, 22(1): 3-5. doi: 10.1111/dom.13874 .
doi: 10.1111/dom.13874
|
| [9] |
SARGEANT J A, BRADY E M, ZACCARDI F, et al. Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials[J]. Diabetologia, 2020, 63(8): 1516-1520. doi: 10.1007/s00125-020-05174-9 .
doi: 10.1007/s00125-020-05174-9
|
| [10] |
LASCAR N, BROWN J, PATTISON H, et al. Type 2 diabetes in adolescents and young adults[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 69-80. doi: 10.1016/S2213-8587(17)30186-9 .
doi: 10.1016/S2213-8587(17)30186-9
|
| [11] |
NORMAN G, MONTEIRO S, SALAMA S. Sample size calculations: should the emperor's clothes be off the peg or made to measure[J]. BMJ,2012,345: e5278. doi: 10.1136/bmj.e5278 .
doi: 10.1136/bmj.e5278
|
| [12] |
JUFAR A H, LANKADEVA Y R, MAY C N, et al. Renal functional reserve: From physiological phenomenon to clinical biomarker and beyond[J]. Am J Physiol Regul Integr Comp Physiol, 2020, 319(6): R690-R702.doi: 10.1152/ajpregu.00237.2020 .
doi: 10.1152/ajpregu.00237.2020
|
| [13] |
SÁNCHEZ-HIDALGO J J, SUÁREZ-CUENCA J A, LOZANO-NUEVO J J, et al. Urine transferrin as an early endothelial dysfunction marker in type 2 diabetic patients without nephropathy: A case control study[J]. Diabetol Metab Syndr, 2021, 13(1): 128.doi: 10.1186/s13098-021-00745-1 .
doi: 10.1186/s13098-021-00745-1
|
| [14] |
郝宝顺, 张辉, 刘雪莲, 等. 糖尿病早期肾病患者血管内皮功能的超声研究[J]. 中华临床医师杂志(电子版), 2011, 5(18): 5331-5335. doi: 10.3877/cma.j.issn.1674-0785. 2011. 18.021 .
doi: 10.3877/cma.j.issn.1674-0785. 2011. 18.021
|
| [15] |
MAGLIANO D J, SACRE J W, HARDING J L, et al. Young-onset type 2 diabetes mellitus-implications for morbidity and mortality[J]. Nat Rev Endocrinol, 2020, 16(6): 321-331. doi: 10.1038/s41574-020-0334-z .
doi: 10.1038/s41574-020-0334-z
|
| [16] |
刘晓, 白海龙, 边云. 糖尿病肾病患者血栓相关因子动态评估对血栓风险的预测价值[J]. 中国临床研究, 2024, 37(7): 1055-1059.doi: 10.13429/j.cnki.cjcr.2024.07.014 .
doi: 10.13429/j.cnki.cjcr.2024.07.014
|
| [17] |
LASZIK Z G, ZHOU X J, FERRELL G L, et al. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis[J]. Am J Pathol, 2001, 159(3): 797-802. doi: 10.1016/S0002-9440(10)61753-1 .
doi: 10.1016/S0002-9440(10)61753-1
|
| [18] |
DROŻDŻ D, ŁĄTKA M, DROŻDŻ T, et al. Thrombomodulin as a New Marker of Endothelial Dysfunction in Chronic Kidney Disease in Children[J]. Oxid Med Cell Longev, 2018, 2018: 1619293. doi: 10.1155/2018/1619293 .
doi: 10.1155/2018/1619293
|
| [19] |
张心钰, 田风胜. 纤维蛋白原与糖尿病肾病相关性的研究进展[J]. 中国医药导报, 2023, 20(18): 61-64.doi: 10.20047/j.issn1673-7210.2023.18.13 .
doi: 10.20047/j.issn1673-7210.2023.18.13
|
| [20] |
ISERMANN B, VINNIKOV IA, MADHUSUDHAN T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis[J]. Nat Med, 2007,13(11): 1349-58.doi: 10.1038/nm1667 .
doi: 10.1038/nm1667
|
| [21] |
YANG S M, KA S M, WU H L, et al. Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis[J]. Diabetologia, 2014,57(2): 424-434.doi: 10.1007/s00125-013-3115-6 .
doi: 10.1007/s00125-013-3115-6
|
| [22] |
BALDRIGHI M, MALLAT Z, LI X. NLRP3 inflammasome pathways in atherosclerosis[J]. Atherosclerosis, 2017, 267: 127-138. doi: 10.1016/j.atherosclerosis.2017.10.027 .
doi: 10.1016/j.atherosclerosis.2017.10.027
|
| [23] |
IWASHIMA Y, SATO T, WATANABE K, et al. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy[J]. Diabetes, 1990, 39(8): 983-988. doi: 10.2337/diab.39.8.983 .
doi: 10.2337/diab.39.8.983
|
| [24] |
LI W, SHENG S, ZHU F. Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis[J]. Thromb Res, 2025, 249: 109302. doi: 10.1016/j.thromres.2025.109302 .
doi: 10.1016/j.thromres.2025.109302
|
| [25] |
HUANG Y, FU R, ZHANG J, et al. Dynamic changes in metabolic syndrome components and chronic kidney disease risk: A population-based prospective cohort study[J]. BMC Endocr Disord, 2025, 25(1): 137. doi: 10.1186/s12902-025-01958-5 .
doi: 10.1186/s12902-025-01958-5
|
| [26] |
GUAN M, CUI S, SONG H, et al. Association between the triglyceride to high-density lipoprotein cholesterol ratio and diabetes mellitus likelihood in patients with chronic kidney disease[J]. BMC Nephrol, 2025, 26(1): 470. doi: 10.1186/s12882-025-04377-9 .
doi: 10.1186/s12882-025-04377-9
|
| [27] |
KEANE W F, TOMASSINI J E, NEFF D R. Lipid abnormalities in patients with chronic kidney disease: Implications for the pathophysiology of atherosclerosis[J]. J Atheroscler Thromb, 2013, 20(2): 123-33. doi: 10.5551/jat.12849 .
doi: 10.5551/jat.12849
|
| [28] |
GONG L, WANG C, NING G, et al. High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study[J]. Diabetes Obes Metab, 2021, 23(11): 2551-2560. doi: 10.1111/dom. 14502 .
doi: 10.1111/dom. 14502
|
| [29] |
PONTREMOLI R, DESIDERI G, ARCA M, et al. Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate and risk of end-stage kidney disease in a real-word Italian cohort: Evidence from the TG-RENAL Study[J]. Eur J Intern Med, 2023, 111: 90-96. doi: 10.1016/j.ejim.2023.02.019 .
doi: 10.1016/j.ejim.2023.02.019
|
| [30] |
REN L, CUI H, WANG Y, et al. The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects[J]. Biomed Pharmacother, 2023, 161: 114465. doi: 10.1016/j.biopha.2023.114465 .
doi: 10.1016/j.biopha.2023.114465
|
| [31] |
YU H, XIE L F, CHEN K, et al. Initiating Characteristics of Early-onset Type 2 Diabetes Mellitus in Chinese Patients[J]. Chin Med J (Engl), 2016,129(7): 778-784. doi: 10.4103/0366-6999.178959 .
doi: 10.4103/0366-6999.178959
|
| [32] |
REZAEE A, DARROUDI S, YAVARI A, et al. Novel anthropometric and lipid indices as predictors of chronic kidney disease: Insights from a decade-long cohort study[J]. J Health Popul Nutr, 2025, 44(1): 227. doi: 10.1186/s41043-025-00924-0 .
doi: 10.1186/s41043-025-00924-0
|
| [33] |
DI SESSA A, PASSARO A P, COLASANTE A M, et al. Kidney damage predictors in children with metabolically healthy and metabolically unhealthy obesity phenotype[J]. Int J Obes (Lond), 2023, 47(12): 1247-1255. doi: 10.1038/s41366-023-01379-1 .
doi: 10.1038/s41366-023-01379-1
|
| [34] |
BJERGFELT S S, SØRENSEN I, HJORTKJÆR H Ø, et al. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification[J]. PLoS One, 2021, 16(11): e0260417. doi: 10.1371/journal.pone.0260417 .
doi: 10.1371/journal.pone.0260417
|
| [35] |
WATRAL J, FORMANOWICZ D, PEREK B, et al. Comprehensive proteomics of monocytes indicates oxidative imbalance functionally related to inflammatory response in chronic kidney disease-related atherosclerosis[J]. Front Mol Biosci, 2024, 11: 1229648. doi: 10.3389/fmolb.2024.1229648 .
doi: 10.3389/fmolb.2024.1229648
|
| [36] |
WANG L, WANG J, JI J, et al. Associations between inflammatory markers and carotid plaques in CKD: Mediating effects of eGFR-a cross-sectional study[J]. BMC Nephrol, 2024, 25(1): 374. doi: 10.1186/s12882-024-03826-1 .
doi: 10.1186/s12882-024-03826-1
|
| [37] |
HIRANO T, SATOH N, KODERA R, et al. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort[J]. J Diabetes Investig, 2022, 13(4): 657-667. doi: 10.1111/jdi. 13697 .
doi: 10.1111/jdi. 13697
|
| [38] |
HIRANO T. Pathophysiology of Diabetic Dyslipidemia[J]. J Atheroscler Thromb, 2018, 25(9): 771-782. doi: 10.5551/jat.RV17023 .
doi: 10.5551/jat.RV17023
|
| [39] |
叶健华, 赵玉钏. 2型糖尿病缓解标准与治疗策略[J]. 实用医学杂志,2023,39(14):1729-17320. doi: 10.3969/j.issn.1006-5725.2023.14.001 .
doi: 10.3969/j.issn.1006-5725.2023.14.001
|